Year: 2025
Type: article
Abstract: Leukemia is a group of cancers affecting the bone marrow and blood, leading to an overproduction of abnormal white blood cells that impair the body's ability to produce healthy blood cells, causing complications such as anemia, bleeding disorders, and weakened immunity. It is one of the most common cancers in both adults and children, with incidence rates varying by age, sex, and geography. Although the exact causes remain unclear, factors such as genetic mutations, exposure to radiation, certain chemicals, and infections have been linked to its development. Recent advances in the molecular understanding of leukemia have enabled the development of targeted therapies, improving treatment outcomes and survival rates. Leukemia is classified into four main types—ALL, AML, CLL, and CML—each presenting unique challenges in treatment and prognosis, with outcomes influenced by factors like age and genetic mutations. Despite improvements in chemotherapy, targeted therapies, and immunotherapies, significant challenges such as drug resistance, disease relapse, and the aggressive nature of some leukemia types persist. Early diagnosis through blood tests, bone marrow biopsies, and genetic profiling is critical for determining the most effective, personalized treatment plans. Novel therapies, including CAR-T cell therapy and CRISPR-based approaches, are showing promise in overcoming resistance and targeting specific genetic mutations driving the disease. While advances have been substantial, ongoing research is essential to further refine these treatments, improve long-term outcomes, and address the complexities of drug resistance and relapse in high-risk patients
Authors: Tithi Patel, Tawil Bill
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4412632678